Changes in the illness perceptions of patients with rheumatoid arthritis over the first year of methotrexate therapy

James M. Gwinnutt 1, Sam Norton 2,3, Kimme L. Hyrich 1,4, Mark Lunt 1, Anne Barton 4,5, Lis Cordingley 1,4 and Suzanne M. M. Verstappen 1,4; for the RAMS co-investigators

Abstract

Objectives. To describe the illness perceptions of patients with RA over the first year of MTX treatment, and the association between illness perceptions and outcomes.

Methods. Data came from the Rheumatoid Arthritis Medication Study (RAMS), a UK multicentre cohort study of RA patients starting MTX for the first time. Patients were assessed at baseline, and at 6 and 12 months. Patients completed the Brief Illness Perception Questionnaire (B-IPQ) at each assessment, as well as other patient-reported outcomes (PROs). The inflammation score (2-component DAS28) was calculated. Subgroups of patients with similar trajectories across the eight (B-IPQ) items were identified using a latent class growth model. Predictors of group membership were identified using multinomial logistic regression. Associations between subgroups and PROs over follow-up were assessed using linear mixed models.

Results. Three subgroups were identified in the analysis population (N = 1087): Positive illness perceptions (N = 322), Negative illness perceptions (N = 534) and Improvers (N = 231) who switched from negative to positive illness perceptions over follow-up. Baseline disability was associated with group membership [Positive vs Negative: relative risk ratio (RRR) 0.37, 95% CI: 0.25, 0.54; Improvers vs Negative: RRR 0.60, 95% CI: 0.43, 0.83], as were other PROs (pain, fatigue, anxiety, depression). The Negative group had worse disability, pain and fatigue over follow-up compared with the other groups, controlling for inflammation.

Conclusion. Negative illness perceptions are associated with poor PROs over time. The Improvers subgroup illustrated that illness perceptions can change in RA. Illness perceptions represent a potential therapeutic target that should be assessed using randomized trials.

Key words: Rheumatoid Arthritis, Illness Perceptions, Health Psychology, Epidemiology, Disability


Introduction

A biopsychosocial approach to disease recognizes that people’s experiences of long-term illness are mediated by biological, psychological and social factors [1]. RA is a chronic condition characterized by inflammation of joints, chronic disability and pain [2]. Outcomes in RA are related to biological factors, such as inflammation and serological markers [3–5], but also to psychosocial factors, such as higher helplessness and perceived stress [6, 7].

One set of psychological factors that are important in predicting outcomes in RA are patients’ illness perceptions. Leventhal et al’s Common-Sense Model of Self-Regulation states that people’s beliefs about their disease (i.e., illness perceptions) do not necessarily match their biological condition and yet are associated with outcomes [8]. A study of 134 Norwegian patients undergoing one or more weeks of rheumatology rehabilitation illustrated that poor illness perceptions were associated with worse pain, function and mental health 12 months later [9]. An Austrian cross-sectional study of 120 RA patients reported associations between stronger beliefs in the negative consequences of RA and physical health–related quality of life [10]. Another cross-sectional study of 230 patients with RA from the UK showed that illness perceptions were associated with increased psychological distress, independent of disease activity [11]. A study of 189 patients with established RA (mean disease duration = 12.6 years) from six UK hospitals used latent profile analysis to identify two subgroups of patients based on their illness perceptions. Those in the negative illness perception group had worse function, pain and distress than the positive illness group at 6 months, after adjustment for differences in clinical and demographic variables at baseline [12].

These studies assessed illness perceptions at a single time-point; however, illness perceptions have been shown to change over time in other musculoskeletal diseases. For instance, Bijsterbosch et al. showed that people with OA reported feeling that their OA was more chronic and less controllable at 6 years compared with baseline, but that they experienced fewer negative emotions because of their OA [13]. Indeed, Leventhal et al’s original model does not consider illness perceptions to be fixed for individuals. An individual’s perceptions evolve over time, based on the evolving symptoms of their disease and their attempts to cope with these symptoms [14]. A person’s perceptions can change considerably, particularly early in the disease course, while their mental schema of the illness (i.e., illness representation) is being formed [9]. Given that there are more effective treatments available for RA than OA, but also that RA symptoms typically fluctuate more over time than OA, one may expect different changes in illness perception over time in patients with RA compared with OA. However, at present there are few data on how illness perceptions change over time in patients with RA. Our hypothesis is that there are distinct subgroups of patients characterized by changes in their illness perceptions over 12 months, and that these illness perceptions are associated with outcomes. The aims of the current study were (i) to characterize how the illness perceptions of people with RA changed over 12 months following the initiation of MTX, (ii) to assess whether there are distinct groups of patients with similar trends in illness perceptions over time, (iii) to assess baseline factors predicting membership of these groups and (iv) to describe the outcomes for these groups over 12 months.

Methods

Patients with RA who were about to start MTX treatment for the first time were recruited to the Rheumatoid Arthritis Medication Study (RAMS), a prospective cohort study based in the UK [15]. Patients were recruited from 38 centres across the UK from 2008. Patients were included in the analysis if they had illness perception data on at least one item at baseline (pre-treatment) and at either 6 or 12 months. Patients were excluded if they had >24 months of symptom duration at baseline (see Supplementary Fig. S1, available at Rheumatology online, for flow-diagram of exclusions). RAMS ethical approval was obtained from the National Research Ethics Service Central Manchester Research Ethics Committee (ref: 08/H1008/25), and all patients gave their written informed consent.

Assessments

Demographics were collected at baseline, and patients completed questionnaires at baseline and at 6 and 12 months. Each patient’s socio-economic status was defined based on where they lived, using the Index of Multiple Deprivation 2010 (IMD) [16], coded as quintiles, with the lowest quintile being the most deprived. Patients completed the British version of the HAQ – Disability Index (HAQ-DI), a self-reported measure of functional disability [17]. Patients also completed pain and fatigue visual analogue scales (VASs) and the Hospital Anxiety and Depression Scale (HADS), calculating separate scores for the anxiety and depression subscales [18]. Blood samples were taken at each assessment and stored in –80°C freezers for analysis including: CRP (mg/l) level at each assessment and RF positivity (latex test) at baseline. The 2-component Disease Activity Score (DAS28-2C) was calculated at each assessment. This is a combination of swollen joint count and CRP, representing inflammation level rather than global disease activity [19]. The 4-component DAS28 (swollen and tender joint counts, CRP and patient global assessment) was also calculated [20, 21].

Illness perceptions

Illness perceptions were measured using the Brief Illness Perception Questionnaire (B-IPO) [22], modified for patients with RA. This eight-item questionnaire was developed with the aim of being a very short yet valid
Illness perceptions in rheumatoid arthritis

Results

In total, 1087 patients were included in the analysis. The median age of the cohort was 61 years [interquartile range (IQR): 52, 70] at baseline, and 708 (65.1%) patients were women. Patients had moderate disease activity and disability at baseline [median (IQR): DAS28 = 4.1 (3.2, 5.1); HAQ = 1.0 (0.5, 1.5), Table 1]. The illness perceptions of the patients at baseline illustrated that patients perceived that their arthritis affected them moderately [mean (s.d.): B-IPQ1 = 5.6 (2.5), B-IPQ5 = 6.2 (2.4), B-IPQ8 = 5.4 (2.9)], that they had moderate control over their arthritis [mean (s.d.): B-IPQ3 = 4.2 (2.7)], that they thought their arthritis would last for a long time [mean (s.d.): B-IPQ2 = 8.2 (2.5)], but that treatment would be helpful [mean (s.d.): B-IPQ4 = 7.8 (1.9)] (Table 2). Furthermore, patients were highly concerned about their arthritis [mean (s.d.): B-IPQ6 = 7.9 (2.3)], but they understood their arthritis well [mean (s.d.): B-IPQ7 = 6.9 (2.4)].

B-IPQ change over 12 months

In general, the illness perceptions of patients improved over 12 months (Fig. 1; Table 2). Patients rated their illness as affecting them less and they felt they had more control over their illness, were less concerned about their illness and understood their illness better. The only two B-IPQ items that did not change were B-IPQ2 and B-IPQ4, indicating that patients’ perceptions of the chronicity of their illness and the effectiveness of their treatments did not change over 12 months.

Latent trajectories of B-IPQ scores over 12 months

The latent class analysis identified three latent classes of B-IPQ scores over follow-up (Fig. 2; Table 2). B-IPQ items 1, 5, 6 and 8 showed the most heterogeneity, indicating that the classes were separated mainly by perceptions of the severity of their illness and the impact on patients physically and emotionally. The Negative B-IPQ trajectory group [N = 534 (49.1%)] had high scores on all B-IPQ items at baseline, with the majority of these items improving by approximately one unit by 12 months, the only exceptions being B-IPQ2 (longevity) and B-IPQ4 (treatment efficacy), which did not change in this group over follow-up. The Positive B-IPQ trajectory group [N = 322 (29.6%)] had significantly lower scores on all B-IPQ items than the Negative group, other than B-IPQ7 (illness comprehensibility), which did not differ between the trajectories. The final group comprised patients whose B-IPQ scores improved over follow-up [N = 231 (21.3%)]. For the majority of B-IPQ items, the Improvers group’s baseline B-IPQ scores were similar to those of the Negative trajectory group. However, by 6 months the Improvers group’s scores were similar to the Positive trajectory group’s, and this was maintained to 12 months. The only item where this was not seen were B-IPQ4 (treatment efficacy) and B-IPQ7 (illness comprehensibility), where the Improvers group had slightly better scores over follow-up than the other two groups (Table 2).
Predictors of trajectory group membership

The results of the component of the multinomial logistic regression comparing the Positive vs Negative trajectory groups showed that lower baseline disability was strongly associated with being in the Positive group compared with the Negative group [relative risk ratio (RRR) 0.37 per unit increase in HAQ, 95% CI: 0.25, 0.54]. Lower pain, lower fatigue, lower depression and lower anxiety were also all independently associated with being in the Positive trajectory group compared with the Negative group (Table 3). However, baseline inflammation level (DAS28-2C) did not predict Positive vs Negative trajectory group membership (RRR 0.99 per unit increase in DAS28-2C, 95% CI: 0.86, 1.13).

The factors that predicted patients being in the Improvers group over the Negative trajectory group were lower disability (RRR 0.60 per unit increase in HAQ, 95% CI: 0.43, 0.83), fatigue (RRR 0.73 per standard deviation increase in fatigue VAS, 95% CI: 0.58, 0.91) and anxiety (RRR 0.94 per unit increase in HADS anxiety, 95% CI: 0.89, 0.99). Higher inflammation level was associated with higher odds of being in the Improvers group over the Negative group (RRR 1.13 per unit increase in DAS28-2C, 95% CI: 1.00, 1.27) (Table 3).

Outcomes over 1 year

Disability, pain and fatigue scores were all lower in the Positive and Improvers trajectory groups compared with the Negative perceptions group, after controlling for age and gender [mean difference (95% CI), Positive vs Negative perceptions group: HAQ = −0.75 (−0.82, −0.67), pain VAS = −24.9 (−27.3, −22.6), fatigue VAS = −27.1 (−29.9, −24.4); Improvers vs Negative perceptions group: HAQ = −0.59 (−0.67, −0.50), pain VAS = −19.0 (−21.6, −16.4), fatigue VAS = −22.5 (−25.5, −19.4)]. Patients in the Positive and Improvers trajectory groups had lower DAS28-2C over follow-up, controlling for age and gender [mean difference (95% CI), Positive vs Negative: −0.68 (−0.84, −0.52); Improvers vs Negative: −0.42 (−0.60, −0.25)] (see Supplementary Table S1, available at Rheumatology online, for comparison of DAS28 and remission rates between groups).

When controlling for time-varying inflammation score,
### Table 2: Brief Illness Perception items over time for the total cohort and stratified by B-IPQ trajectory group

| #  | B-IPQ item                                                                 | Total cohort (N = 1087) | Negative (N = 534) | Positive (N = 322) | Improvers (N = 231) |
|----|-----------------------------------------------------------------------------|-------------------------|--------------------|---------------------|----------------------|
|    |                                                                            | Baseline, mean (s.d.)   | 12 months, mean (s.d.) | Baseline, mean (s.d.) | 12 months, mean (s.d.) | Baseline, mean (s.d.) | 12 months, mean (s.d.) |
| 1  | How much does arthritis affect your life? (10 = severely affects life)      | 5.6 (2.5)               | 4.3 (2.6)           | 7.0 (1.8)           | 5.5 (2.4)            | 2.8 (1.5)           | 2.9 (2.0)            | 6.3 (1.9)           | 3.5 (2.7)           |
| 2  | How long do you think your arthritis will continue? (10 = forever)         | 8.2 (2.5)               | 8.7 (2.4)           | 8.6 (2.1)           | 9.0 (1.8)            | 7.4 (3.1)           | 8.4 (2.8)            | 8.2 (2.3)           | 8.4 (2.8)           |
| 3  | How much control do you feel you have over your arthritis? (10 = extreme amount of control) | 4.2 (2.7)               | 5.6 (2.7)           | 3.7 (2.6)           | 5.1 (2.6)            | 5.1 (2.8)           | 6.0 (2.7)            | 4.0 (2.6)           | 6.0 (2.9)           |
| 4  | How much do you think your treatment can help your arthritis? (10 = extremely helpful) | 7.8 (1.9)               | 7.8 (2.2)           | 7.6 (1.9)           | 7.5 (2.2)            | 8.1 (1.9)           | 8.1 (2.2)            | 8.1 (1.8)           | 8.3 (2.3)           |
| 5  | How much do you experience symptoms from your illness? (10 = many severe symptoms) | 6.2 (2.4)               | 4.7 (2.5)           | 7.4 (1.7)           | 5.7 (2.3)            | 3.7 (1.8)           | 3.7 (2.3)            | 6.7 (1.8)           | 4.1 (2.7)           |
| 6  | How concerned are you about your arthritis? (10 = extremely concerned)     | 7.9 (2.3)               | 6.1 (3.0)           | 8.8 (1.6)           | 7.3 (2.6)            | 6.1 (2.6)           | 4.8 (2.9)            | 8.3 (1.8)           | 5.3 (2.9)           |
| 7  | How well do you feel you understand your arthritis? (10 = understand very clearly) | 6.9 (2.4)               | 7.4 (2.3)           | 6.7 (2.5)           | 7.3 (2.4)            | 6.8 (2.5)           | 7.4 (2.3)            | 7.5 (2.2)           | 7.8 (2.4)           |
| 8  | How much does your arthritis affect you emotionally (e.g. does it make you angry, scared, upset or depressed?) (10 = extremely affected) | 5.4 (2.9)               | 4.2 (3.0)           | 6.7 (2.4)           | 5.6 (2.8)            | 3.1 (2.4)           | 2.7 (2.4)            | 5.6 (2.9)           | 3.4 (2.8)           |

B-IPQ: Brief Illness Perception Questionnaire; N: number.
patients in the Positive and Improvers trajectory groups still had lower disability, pain and fatigue scores compared with the Negative perceptions group [mean difference (95% CI), Positive vs Negative perceptions group: HAQ = −0.67 (−0.74, −0.60), pain VAS = −21.0 (−23.3, −18.7), fatigue VAS = −25.0 (−27.8, −22.2); Improvers vs Negative perceptions group: HAQ = −0.54 (−0.62, −0.46), pain VAS = −16.6 (−19.1, −14.1), fatigue VAS = −21.1 (−24.2, −18.1)].

Discussion
This study illustrates how illness perceptions change in a large cohort of patients with RA over the first year of treatment with MTX. This was a cohort of patients with recent onset of symptoms. At baseline, their understanding of the long-term implications of their diagnosis would have been more limited than that of those with long-standing disease, thereby increasing
their uncertainty about the long-term impact. After baseline, the majority of illness perceptions improved to a small degree in the whole sample. However, patients’ beliefs about the chronicity of RA and the efficacy of treatment did not change substantially over 12 months. Latent class analysis identified three groups of patients with distinct trajectories of illness perceptions over 12 months. One group had consistently negative illness perceptions, a second group had consistently positive illness perceptions and the third group switched from negative to positive illness perceptions in the first 6 months following initiation of treatment. Disability at baseline was strongly associated with trajectory group, as were pain, fatigue, anxiety and depression. Comparing the outcomes of the three groups showed that the Positive and Improvers groups had lower disability, pain and fatigue over 12 months compared with the Negative perception group, independent of inflammation level.

The majority of the illness perceptions for the whole cohort improved by approximately one unit over the
course of 12 months. This is at odds with an analysis of 75 women with RA, which reported that patients’ illness perceptions did not change over 1 and 2 years of follow-up [31]. However, that study analysed prevalent cases of RA with a mean of 11 years since diagnosis at baseline. Potentially, illness perceptions have stabilized this long after symptom onset, as would be expected according to the underlying theory [8]. Furthermore, these patients developed RA in the 1990s, before treat-to-target strategies were widely implemented, and expectations of short-term and long-term outcomes may have been different compared with patients recruited to RAMS over the last 10 years.

Latent profile analysis has been applied to the baseline illness perceptions of a cohort of patients with RA in the past [12]. Norton et al. identified two groups of patients—one characterized by negative illness perceptions and one by positive illness perceptions. Assessing only the baseline data of the RAMS patients would suggest a similar class structure. However, the incorporation of longitudinal data in the current study revealed a third illness perception group, accounting for about one in five patients, that switches from negative to positive illness perceptions over the first 6 months. As illness perceptions can potentially change in the first few months after starting treatment, this potentially highlights the importance of how information is framed by clinicians when providing information at the time of diagnosis and in the early phases of the disease.

Interestingly, inflammation was not independently associated with being in the Positive trajectory group over the Negative group. Instead, patient-reported outcomes were more important in predicting group membership. Patients with higher disability, pain, fatigue, anxiety or depression were more likely to have negative illness perceptions compared with the Positive and Improvers groups. In a previous study, the inflammation components of the DAS28 have been shown to be weakly associated with illness perceptions and not associated with the psychological outcomes of patients with RA [32], and long-term observational research has illustrated a disconnect between secular changes in inflammation levels and disability as well as in other patient-reported outcomes [33–35]. This indicates the need to focus on other aspects of disease symptomology alongside inflammation in order to achieve optimal outcomes for people with RA. Higher inflammation was weakly associated with increased odds of being in the Improvers group over the Negative group. Potentially, patients with higher inflammation scores and negative perceptions at baseline noted a larger change in their inflammation level over time, as their inflammation scores had more room for change, prompting a change in the perception of their condition.

When the patient-reported outcomes of the three illness perception groups were compared over 1 year, patients in the Negative illness perception group had consistently worse outcomes, independent of longitudinal inflammation. Patients in the Positive and Improvers groups had lower disability, pain and fatigue over 1 year compared with the Negative illness perception group, holding longitudinal inflammation level constant. The 2-component DAS28 was chosen as the variable to adjust for, because we aimed to adjust for inflammation level,

| TABLE 3 | Results from multivariable multinomial logistic regression model predicting trajectory group membership from baseline variables |
|---|---|
| | Positive vs negative trajectory group | Improvers vs negative trajectory group |
| Baseline variable | RRR (95% CI) | RRR (95% CI) |
| Age (years) | 1.01 (0.99, 1.03) | 1.00 (0.99, 1.01) |
| Men vs women | 0.72 (0.48, 1.06) | 0.91 (0.63, 1.31) |
| Disease duration (months) | 1.00 (0.97, 1.03) | 1.00 (0.97, 1.03) |
| Smoking | 0.96 (0.64, 1.43) | 0.95 (0.66, 1.38) |
| Ex vs Never smoker | 1.06 (0.61, 1.81) | 0.71 (0.42, 1.20) |
| Current vs Never smoker | 1.01 (0.88, 1.17) | 1.03 (0.90, 1.17) |
| IMD, per quintile increase | 0.99 (0.86, 1.13) | 1.13 (1.00, 1.27) |
| DAS28-2C | 0.37 (0.25, 0.54) | 0.60 (0.43, 0.83) |
| HAQ | 0.98 (0.97, 0.99) | 1.00 (0.99, 1.01) |
| Pain VAS | 0.52 (0.40, 0.67) | 0.97 (0.77, 1.23) |
| Natural scale | 0.98 (0.97, 0.99) | 0.99 (0.98, 1.00) |
| Standardized scale | 0.60 (0.47, 0.77) | 0.73 (0.58, 0.91) |
| Fatigue VAS | 0.91 (0.85, 0.97) | 0.94 (0.89, 0.99) |
| Natural scale | 0.90 (0.84, 0.98) | 0.97 (0.91, 1.04) |
| Standardized scale | 1.38 (0.88, 2.17) | 1.13 (0.75, 1.71) |

B-IPQ: Brief Illness Perception Questionnaire; DAS28-2C: 2-Component Disease Activity Score; HADS: Hospital Anxiety and Depression Scale; IMD: Index of Multiple Deprivation 2010; RRR: relative risk ratio; VAS: Visual Analogue Scale.
rather than global disease activity (i.e. the DAS28, which includes both inflammation measures and subjective components). Adjusting for the 4-component DAS28 may have ‘adjusted away’ some of the association between illness perceptions and patient-reported outcomes, as some of the components of the DAS28 will be measuring similar aspects of disease to the patient-reported outcomes (e.g. tender joint count and VAS pain).

Norton et al. reported that patients with positive illness perceptions had better outcomes over 6 months than patients with negative illness perceptions [12], and Van der Elst et al. reported that baseline illness perceptions predicted poor patient-reported outcomes, despite good control of disease (DAS28-CRP < 2.6) [36]. Furthermore, Van der Elst et al. also showed that changes in disease activity were associated with changes in illness perceptions over 1 year in early RA [37]. However, it is unclear whether illness perceptions shape current and future outcomes, or are a reflection of the severity of patients’ outcomes. An analysis using structural equation modelling illustrated that past and present illness perceptions form a chain that mediates the relationship between past and current functioning in patients with RA [38]. The reciprocal nature of the relationship between illness perceptions and patient-reported outcomes has also been demonstrated in other rheumatic diseases (SLE and SSc) [39]. This is in line with Leventhal et al.’s idea of a cyclical, dynamic relationship between illness perceptions and other outcomes, whereby the initial shock of a chronic condition alongside other factors (e.g. self-assessed health status, role identities, culture) moulds the patient’s illness perceptions. These illness perceptions influence the patient’s ability to adapt to their condition, and subsequently the success of these adoptions influences the patient’s later illness perceptions [40], suggesting that interventions should be implemented early in the disease course, before this cyclical relationship can spiral out of control or negative perceptions become embedded and fixed. This is illustrated in our data, whereby the Improvers group showed improvements in their illness perceptions in the first 6 months of follow-up after treatment initiation.

Trials in other conditions have illustrated that interventions aiming to promote positive illness perceptions and beliefs can lead to improvements in symptoms, self-management and quality of life [41–44], and studies in RA have shown that beliefs and illness perceptions are linked to adherence [45, 46]. Given the intimate link between illness perceptions and outcomes in RA, demonstrated by this and other studies, interventions to improve the illness perceptions of patients with negative illness perceptions at treatment onset may have the potential to improve long-term outcomes through increased ability to adapt, better adherence to treatment and improvements in self-management, although randomized controlled trials are required to assess the efficacy of any such interventions.

The current study has a number of strengths. To our knowledge, this is the largest prospective observational study to consider illness perceptions in RA, including over 1000 patients, resulting in precise estimates of the associations between illness perception groups and outcomes. The longitudinal nature of the study means that the evolution of patients’ illness perceptions can be described and analysed. Limitations of the study include the relatively limited data available on other important factors in Leventhal et al.’s self-regulation theory [40], meaning that important precipitants of illness perceptions (e.g. patients’ role identities) cannot be included in the analyses. Furthermore, education data were only available for a proportion of patients and therefore were not included in the analyses.

In conclusion, we have demonstrated that patients’ illness perceptions generally improve to a small degree in the first year following the initiation of MTX therapy. We have described three distinct illness perception trajectory groups: Positive, Negative and Improvers. The likelihood of being in the Negative illness perception group was strongly associated with worse patient-reported outcomes, and patients in the Positive and Improvers group had improved outcomes over 1 year compared with the Negative group. The observation that the beliefs held by the Improvers group became more positive over time illustrates the potential importance of identifying early opportunities to intervene with appropriate interventions to improve illness perceptions, which should be assessed using randomized controlled trials.

Acknowledgments

The authors thank the patients involved in the Rheumatoid arthritis Medication Study (RAMS), as well as the clinical staff at each of the recruiting centres. Thanks also to the data management team at the University of Manchester. J.G. is supported by a Skills Development Fellowship from the Medical Research Council. This research was supported by the NIHR Manchester Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Funding: This work was supported by Versus Arthritis (grant numbers 20385, 20380) and the NIHR Manchester Biomedical Research Centre.

Disclosure statement: The authors have declared no conflicts of interest.

Data availability statement

The data underlying this article cannot be shared publicly for the privacy of individuals that participated in the study. The data will be shared on reasonable request to the corresponding author.
Supplementary data

Supplementary data are available at *Rheumatology* online.

References

1. Cieza A, Stucki G. Understanding functioning, disability, and health in rheumatoid arthritis: the basis for rehabilitation care. *Curr Opin Rheumatol* 2005;17:183–9.

2. Smolen JS, Aletaha D, Barton A et al. Rheumatoid arthritis. *Nat Rev Dis Primers* 2018;4:18001.

3. Bukhari M, Lunt M, Harrison BJ et al. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. *Arthritis Rheum* 2002;46:906–12.

4. Courvoisier N, Dougados M, Cantagrel A et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. *Arthritis Res Ther* 2008;10:R106.

5. Drouin J, Harault B. Predictors of clinical response and radiographic progression in patients with rheumatoid arthritis treated with methotrexate monotherapy. *J Rheumatol* 2010;37:1405–10.

6. Nicassio PM, Kay MA, Custodio MK, Irwin MR et al. An evaluation of a biopsychosocial framework for health-related quality of life and disability in rheumatoid arthritis. *J Psychosom Res* 2011;71:79–85.

7. Camacho EM, Verstappen SM, Symmons DP. Association between socioeconomic status, learned helplessness, and disease outcome in patients with inflammatory polyarthritis. *Arthritis Care Res* 2012;64:1225–32.

8. Leventhal H, Brissette I, Leventhal EA. The common-sense model of self-regulation of health and illness. In: LD Cameron, H Leventhal, eds. The self-regulation of health and illness behaviour. London: Routledge, 2003: 42–65.

9. Lechting I, Fjerstad G, Garratt AM. Illness perceptions in patients receiving rheumatology rehabilitation: association with health and outcomes at 12 months. *BMC Musculoskelet Disord* 2013;14:28.

10. Løchting I, Fjerstad G, Garratt AM. Illness perceptions in patients receiving rheumatology rehabilitation: association with health and outcomes at 12 months. *BMC Musculoskelet Disord* 2013;14:28.

11. van Os S, Norton S, Hughes LD, Chilcot J. Illness perceptions account for variation in positive outlook as well as psychological distress in rheumatoid arthritis. *Psychol Health Med* 2012;17:427–39.

12. Norton S, Hughes LD, Chilcot J et al. Negative and positive illness representations of rheumatoid arthritis: a latent profile analysis. *J Behav Med* 2014;37:524–32.

13. Bijstebosch J, Scharloo M, Visser AW et al. Illness perceptions in patients with osteoarthritis: change over time and association with disability. *Arthritis Rheum* 2009;61:1054–61.

14. Hale ED, Trehame GJ, Kitas GD. The common-sense model of self-regulation of health and illness: how can we use it to understand and respond to our patients’ needs? *Rheumatology* 2007;46:904–6.

15. Sergeant JC, Hyrich KL, Anderson J et al. Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). *Arthritis Res Ther* 2018;20:147.

16. Communities and Local Government. *English Indices of Deprivation 2010*: Guidance Document 2010. [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/6222/1871538.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/6222/1871538.pdf) (7 July 2020, date last accessed).

17. Kirwan JR, Reesback JS. *Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis*. Br J Rheumatol 1986; 25:206–9.

18. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983;67:361–70.

19. Hensor EMA, McKeigue P, Ling SF et al. Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. *Rheumatology* 2019;58:1400–9.

20. Prevoo MLL, Van’T Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum* 1995;38:44–8.

21. Fransen J, Welsing P, de Keijzer R, van Riel P. Disease Activity scores using C-reactive protein: CRP may replace ESR in the assessment of RA disease activity [abstract]. *Ann Rheum Dis* 2004;62:151.

22. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. *J Psychosom Res* 2006; 60:631–7.

23. Broadbent E, Wilkes C, Koschwanez H et al. A systematic review and meta-analysis of the Brief Illness Perception Questionnaire. *Psychol Health* 2015;30: 1361–85.

24. Proust-Lima C, Philipps V, Liquet B. Estimation of extended mixed models using latent classes and latent processes: the R Package LCM. *J Stat Softw* 2017;78: 1–56.

25. Auguié B. *gridExtra*: Miscellaneous Functions for “Grid” Graphics 2017. [https://CRAN.R-project.org/package=gridExtra](https://CRAN.R-project.org/package=gridExtra) (28 February 2020, data last accessed).

26. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *Journal of Statistical Software* 2015;67:1–48.

27. van Buuren S, Groothuis-Oudshoorn L. *Mice*: multivariate Imputation by Chained Equations in R. *J Stat Softw* 2011;45:1–67.

28. Robitzsch A, Grund S, Miceadds: Some additional multiple imputation functions, especially for ‘mice’ 2020. [https://CRAN.R-project.org/package=miceadds](https://CRAN.R-project.org/package=miceadds).

29. Venables W, Ripley B. Modern applied statistics with S. 4th edn. New York: Springer, 2002.
30 Wickham H, Averick M, Bryan J et al. Welcome to the tidyverse. J Open Sour Softw 2019;4:1686.

31 Groarke A, Curtis R, Coughlan R, Gsel A. The impact of illness representations and disease on adjustment in women with rheumatoid arthritis: a longitudinal study. Psychol Health 2009;20:597–613.

32 Cordingley L, Prajapati R, Plant D et al. Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis. Arthritis Care Res 2014;66:861–8.

33 Gwinnutt JM, Symmons DPM, Macgregor AJ et al. Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register. Ann Rheum Dis 2018;77:848–54.

34 Carpenter L, Barnett R, Mahendran P et al. Secular changes in functional disability, pain, fatigue and mental well-being in early rheumatoid arthritis. A longitudinal meta-analysis. Semin Arthritis Rheum 2020;50:209–19.

35 Carpenter L, Nikiforou E, Kiely PDW et al. Secular changes in the progression of clinical markers and patient-reported outcomes in early rheumatoid arthritis. Rheumatology 2020;59:2381–91.

36 Van der Elst K, Verschueren P, De Cock D et al. One in five patients with rapidly and persistently controlled early rheumatoid arthritis report poor well-being after 1 year of treatment. RMD Open 2020;6:e001146.

37 Van der Elst K, Verschueren P, Stouten V et al. Patient-reported outcome data from an early rheumatoid arthritis trial: opportunities for broadening the scope of treating to target. Arthritis Care Res 2019;71:1566–75.

38 Karademas EC, Dimitraki G, Papastefanakis E et al. Adaptation to inflammatory rheumatic disease: do illness representations predict patients’ physical functioning over time? A complex relationship. J Behav Med 2018;41:232–42.

39 Arat S, Rassart J, Moons P et al. Prospective associations between illness perceptions and health outcomes in patients with systemic sclerosis and systemic lupus erythematosus: a cross-lagged analysis. Rheumatol Adv Pract 2018;2:ry007.

40 Leventhal H, Halm E, Horowitz C, Leventhal E, Ozakinci G. Living with chronic illness: a contextualized, self-regulation approach. In: S Sutton, A Baum, M Johnston, eds. The SAGE handbook of health psychology. London: Sage, 2005: 197–240.

41 Sadeghi Akbari A, Cheraghi MA, Kazemnejad A, Nomali M, Zakerimoghadam M. Effect of illness perception correction - based educational program on quality of life and self-care in patients with heart failure: a randomized controlled trial. J Caring Sci 2019;8:89–93.

42 Petrie KJ, Cameron LD, Ellis CJ, Buick D, Weinman J. Changing illness perceptions after myocardial infarction: an early intervention randomized controlled trial. Psychosom Med 2002;64:580–6.

43 Weldam SWM, Schuurmans MJ, Zanen P et al. The effectiveness of a nurse-led illness perception intervention in COPD patients: a cluster randomised trial in primary care. ERJ Open Res 2017;3:00115–2016. doi: 10.1183/23120541.00115-2016.

44 Keogh KM, Smith SM, White P et al. Psychological family intervention for poorly controlled type 2 diabetes. Am J Manag Care 2011;17:105–13.

45 Kumar K, Raza K, Nightingale P et al. Determinants of adherence to disease modifying anti-rheumatic drugs in White British and South Asian patients with rheumatoid arthritis: a cross sectional study. BMC Musculoskelet Disord 2015;16:396.

46 Hope HF, Hyrich KL, Anderson J, RAMS co-investigators et al. The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate. Rheumatology 2019;59:213–23.